Hemas Holdings PLC Financial Summary and Investment Analysis

Executive Overview

Hemas Holdings PLC is a leading diversified conglomerate in Sri Lanka operating across Consumer Brands (Home and Personal Care, Learning), Healthcare (Pharmaceutical Distribution and Manufacturing, Hospitals), and Mobility (Maritime and Aviation). Recently, the Group restructured its Healthcare segment into two distinct categories: Life Sciences and Hospitals, to better reflect capital and operational dynamics. The Group has demonstrated strong resilience and growth, navigating through macroeconomic volatility, inflationary pressures, and the severe impacts of Cyclone Ditwah in late 2025. Hemas is actively expanding its international footprint (including operations in Bangladesh and a planned entry into Kenya) and investing heavily in digital transformation, manufacturing self-sufficiency, and premium healthcare delivery.

Key periods covered: Q1 2024 to Q2 2026 (Calendar/Natural Year format).

Financial Performance

Revenue and Profitability Trends

Analysis:

• Revenue Trends: The Group recorded a strong revenue growth trajectory throughout 2024 and 2025, driven by volume growth across Consumer Brands and Healthcare. A slight moderation occurred in Q2 2026 (LKR 28.7 Bn, up 0.9% YoY) due to regulated pharmaceutical pricing delays and intense competition.
• Profitability: The Group achieved record annual earnings of LKR 8.92 Bn for the year ended Q1 2026, marking a 10.7% YoY growth. However, Q2 2026 net profit declined 15.7% YoY to LKR 1.06 Bn, primarily due to a sharp escalation in logistics, fuel, freight, and distribution costs resulting from Middle East geopolitical tensions, which squeezed EBITDA margins (down to 7.8%).
• Margin Dynamics: Gross Profit margins have remained robust (historically 30%-34%), supported by supply chain optimization and portfolio premiumization. The dip in Q2 2026 net margin reflects higher operating expenses that outpaced revenue growth, particularly in the Life Sciences segment, where regulatory price caps delayed cost pass-throughs.

Balance Sheet Analysis

Analysis:

• Asset Growth: Total assets expanded steadily, driven by capacity expansions (e.g., Thalawathugoda hospital, new Morison manufacturing facilities) and strategic inventory buffering against supply chain risks.
• Leverage and Solvency: The Group has successfully deleveraged, transitioning to a net cash-positive position. Gross debt reduced from LKR 12.7 Bn in Q1 2024 to LKR 7.5 Bn in Q1 2026. The gearing ratio improved substantially from 22.4% (Q1 2024) to 11.5% (Q1 2026), reflecting retained earnings accumulation and disciplined capital stewardship.
• Liquidity: The current ratio remains healthy (1.60x - 1.72x), ensuring ample liquidity to support the Group's ambitious USD 100+ Mn investment pipeline.

Cash Flow Analysis

Analysis:

• Operating Cash Flows: The Group consistently generates strong operating cash flows, though a slight dip was observed in the year ended Q1 2026 due to deliberate investments in working capital (inventory build-up to pre-empt geopolitical supply shocks).
• Investing Cash Flows: Capital expenditures were primarily directed towards hospital infrastructure, SAP/IT system upgrades (Project HIVE), and manufacturing modernization.
• Financing Cash Flows: Cash outflows in financing reflect aggressive debt repayments and consistent dividend distributions. The net cash position enables the Group to self-fund its strategic acquisitions.

Key Financial Ratios and Growth Indicators

*\* Adjusted for 1-for-5 share split executed in April 2025.*

Other Indicators:

• Market Share: Dominant positions maintained across sectors. Morison advanced 20 places over four years to become the #23 ranked player in the total private pharmaceutical market by value (and #2 by volume). Atlas maintains >50% market share in stationery.
• Product Launches: Launch of *EmpaMor*, *CilniMor*, *BisoMor*, and *RivoMor* (cardiology/diabetes medications). Entry into the Educational Toys segment via *Atlas PlayPalz*. Generative AI platforms introduced (Baby Cheramy WhatsApp bot, Fio app).

Economic and Market Context

• Macroeconomic Environment: Sri Lanka experienced a post-crisis economic recovery with positive GDP growth (5.0% in CY2025) and stabilized inflation. However, high utility tariffs and VAT implementations continue to strain consumer purchasing power, driving a shift towards value-for-money products.
• Currency and Freight: LKR fluctuations and Middle East conflicts (impacting the Red Sea route) have caused significant volatility in freight costs and import prices.
• Natural Disasters: Cyclone Ditwah in Q4 2025 caused severe physical and economic disruption across Sri Lanka, temporarily depressing consumer demand and disrupting distribution networks.
• Regulatory Environment: The National Medicines Regulatory Authority (NMRA) maintains strict price controls on pharmaceuticals. A new pricing formula accounts for exchange rate movements beyond 5%, though approval lags create short-term margin pressures for the Life Sciences segment.

Future Potential and Outlook

• Internationalization: The Group is executing an ambitious geographic expansion, aiming to increase international revenue from 3% to 10%. A major strategic milestone is the proposed acquisition of a consumer products company in Kenya to serve as a gateway to East Africa.
• Healthcare Expansion: Hemas Hospitals broke ground on a major expansion of its Thalawathugoda facility (targeted for revenue contribution in 2029) and launched specialized centers like the CATH Lab and a paediatric liver unit. Morison is pursuing EU-GMP certification to unlock export markets.
• Digital and Cultural Transformation: The Group is investing heavily in "Future-Proofing" via Project HIVE (data lake), SAP RISE, and Hemas AI Labs to drive data-driven decision-making and operational efficiencies.

Risks and Challenges

• Operational & Margin Risks: Escalating global energy and freight costs threaten operating margins. Regulatory delays in pharmaceutical price adjustments exacerbate this risk.
• Supply Chain Disruptions: Heavy reliance on imported raw materials exposes the Group to geopolitical supply shocks, mitigated by proactive inventory building and supplier diversification.
• Talent Retention: Brain drain and migration of skilled professionals (especially in healthcare) pose constraints on service capacity.
• Mitigation: The Group employs robust Enterprise Risk Management (ERM), maintains a Net Cash position, utilizes forward contracts for FX risks, and focuses on localized manufacturing to reduce import dependency (targeting 40% local medicine sourcing by 2030).

Shareholder and Corporate Information

• Major Shareholders: A Z Holdings (Private) Limited (15.70%), Amagroup Pvt Ltd (15.26%), Saraz Investments (Private) Limited (14.95%), Blueberry Investments (Pvt) Ltd (14.84%).
• Public Holding: 37.55% representing 18,215 shareholders as of Q1 2026.
• Corporate Actions: The company executed a 1-into-5 share split in April 2025 to enhance liquidity.
• Dividends: Consistent dividend history with LKR 0.95 per share paid in the year ended Q1 2026, representing a payout ratio of 31.8%.
• Stock Performance: The share price demonstrated strong momentum, outperforming the ASPI and closing at LKR 32.90 by Q2 2026.

Investment Decision Indicators

Strengths:

• Market Leadership: Dominant market shares in resilient, non-discretionary sectors (Healthcare, Education, Personal Care).
• Robust Financial Health: Zero net debt, strong cash generation, and a high interest cover ratio (13.8x).
• Strategic Growth Pipeline: Clear USD 100 Mn+ capital allocation plan targeting international expansion (Kenya/East Africa) and high-margin healthcare adjacencies.
• ESG Integration: Strong sustainability practices, 100% plastic offset targets, and investments in renewable energy.

Weaknesses:

• Regulatory Vulnerability: The Life Sciences division is highly sensitive to government-mandated price controls which lag behind cost inflation.
• Margin Compression: Recent quarters show EBITDA margin contraction due to high selling, distribution, and freight costs.

Opportunities:

• Export Markets: EU-GMP certification for Morison and the Kenyan acquisition offer significant USD revenue potential.
• Import Substitution: Government mandate to source 40% of national medicine requirements locally provides a massive runway for Morison.

Threats:

• Geopolitical Supply Chain Shocks: Middle East conflicts disrupting maritime routes and escalating crude oil/freight costs.
• Domestic Macro Fragility: Consumer disposable income remains highly sensitive to local tax policies and utility rate hikes.

Overall Assessment: Based on the financial data, Hemas Holdings PLC presents a strong fundamental profile characterized by a transition to a net-cash position, dominant market shares in defensive sectors, and a clear catalyst for future growth through internationalization and healthcare expansion. While near-term margin compression from regulatory lags and geopolitical freight costs is evident, the company's robust balance sheet and strategic pricing power position it well to absorb these shocks. The stock's valuation (P/E ~9.9x) paired with a solid dividend payout and recent share split liquidity enhancements provide a compelling data-driven case for investors seeking long-term exposure to Sri Lankan recovery and regional consumer growth.